Jyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug Candidates
Key Highlights
- ➤Jyong Biotech (MENS) plans Texas manufacturing facility and U.S. operations center
- ➤Facility plan submitted to Texas authorities; formal agency communications are pending
- ➤Proposed facility may add health-supplement production lines, subject to planning, regulation and funding
- ➤Jyong Biotech has no approved drug products available for commercial use
Expert Statements
Fu-Feng Kuo, Chairwoman and Chief Executive Officer of Jyong Biotech
“We believe establishing manufacturing capacity in the United States will support our long-term commercial plans”
Fu-Feng Kuo, Chairwoman and Chief Executive Officer of Jyong Biotech
“Texas offers a favorable business environment and potential state tax incentives, which we believe will allow us to build the infrastructure needed to support the potential commercial activities and operations of our drug candidates, if approved.”
Fu-Feng Kuo, Chairwoman and Chief Executive Officer of Jyong Biotech
“Our commercial strategy in the U.S. targets a significant patient population”
Fu-Feng Kuo, Chairwoman and Chief Executive Officer of Jyong Biotech
“With nearly 35 percent of patients in watchful waiting and almost 10 percent discontinuing drug treatment, we believe our drug candidates, if approved, will address this unmet medical need.”
Jyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug Candidates PR Newswire
NEW TAIPEI CITY, Oct. 16, 2026 /PRNewswire/ -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today announced that it plans to establish a potential new manufacturing facility and U.S. operations center in Texas. The initiative is intended to support the Company's U.S. operations and position it for the potential future commercialization of its proprietary investigational drug candidates, if approved.
Get started
Create a free account to read the full story.